Novavax Inc. [NASDAQ: NVAX] price plunged by -0.94 percent to reach at -$1.97. The company report on June 15, 2021 that Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial.
93% efficacy against predominantly circulating Variants of Concern and Variants of Interest.
91% efficacy in high-risk populations.
A sum of 11139698 shares traded at recent session while its average daily volume was at 3.54M shares. Novavax Inc. shares reached a high of $229.50 and dropped to a low of $200.614 until finishing in the latest session at $207.71.
The one-year NVAX stock forecast points to a potential upside of 19.49. The average equity rating for NVAX stock is currently 2.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $258.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 12, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 14, 2020, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise from $132 to $290, while H.C. Wainwright kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 15.81, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 16.36. The Price to Book ratio for the last quarter was 14.60, with the Price to Cash per share for the same quarter was set at 27.59. Price to Free Cash Flow for NVAX in the course of the last twelve months was 26.14 with Quick ratio for the last quarter at 1.90.
NVAX Stock Performance Analysis:
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.50. With this latest performance, NVAX shares gained by 71.66% in over the last four-week period, additionally plugging by 80.48% over the last 6 months – not to mention a rise of 355.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 65.35, with the RSI for the last a single of trading hit 73.73, and the three-weeks RSI is set at 59.54 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 181.47, while it was recorded at 206.16 for the last single week of trading, and 153.69 for the last 200 days.
Insight into Novavax Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -87.05. Novavax Inc.’s Net Margin is presently recorded at -87.94.
Return on Total Capital for NVAX is now -65.98, given the latest momentum, and Return on Invested Capital for the company is -73.12. Return on Equity for this stock declined to -189.60, with Return on Assets sitting at -47.65. When it comes to the capital structure of this company, Novavax Inc. [NVAX] has a Total Debt to Total Equity ratio set at 76.83. Additionally, NVAX Total Debt to Total Capital is recorded at 43.45, with Total Debt to Total Assets ending up at 30.45. Long-Term Debt to Equity for the company is recorded at 59.35, with the Long-Term Debt to Total Capital now at 33.56.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$528,772 per employee. Receivables Turnover for the company is 3.53 with a Total Asset Turnover recorded at a value of 0.54.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 1.90.
NVAX Stock EPS
With the latest financial reports released by the company, Novavax Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX] Insider Position Details
There are presently around $8,848 million, or 58.20% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 5,893,304, which is approximately 5.261% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 5,473,023 shares of the stock with an approximate value of $1.14 billion in NVAX stocks shares; and FMR LLC, currently with $995.12 million in NVAX stock with ownership of nearly 173.671% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 205 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 10,734,829 shares. Additionally, 199 investors decreased positions by around 6,441,035 shares, while 43 investors held positions by with 25,423,044 shares. The mentioned changes placed institutional holdings at 42,598,908 shares, according to the latest SEC report filing. NVAX stock had 103 new institutional investments in for a total of 3,542,330 shares, while 60 institutional investors sold positions of 1,945,830 shares during the same period.